

U.S.S.N. 09/715,965
Filed: November 17, 2000
Amendment

consisting of heparinase 1 from *Flavobacterium heparinum*, heparinase 2 from *Flavobacterium heparinum*, heparinase 3 from *Flavobacterium heparinum*,] chondroitinase AC from *Flavobacterium heparinum*, [and] chondroitinase B from *Flavobacterium heparinum*, [heparinase from *Bacteroides* strains, heparinase from *Flavobacterium Hp206*, heparinase from *Cytophagia* species,] a chondroitin sulfate degrading [enzymes] enzyme from *Bacteroides* species, a chondroitin sulfate degrading [enzymes] enzyme from *Proteus vulgaris*, a chondroitin sulfate degrading [enzymes] enzyme from *Micrococcus*, a chondroitin sulfate degrading [enzymes] enzyme from *Vibrio* species, a chondroitin sulfate degrading [enzymes] enzyme from *Arthrobacter aurescens*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.

4. (amended) The method of claim [1] 8 wherein the enzyme is a chondroitinase AC.

5. (amended) The method of claim [4] 1 wherein the chondroitinase is chondroitinase AC.

6. (twice amended) The method of claim 1 wherein [at the time] the enzyme is administered to an [the] individual [has] having cancer as evidenced by palpable tumors.

8. (amended) The method of claim 1 wherein the individual has a disorder in which angiogenesis is involved, the disorder being selected from the group consisting of rheumatoid arthritis; psoriasis; ocular angiogenic [diseases] disease, ruberosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints;

U.S.S.N. 09/715,965
Filed: November 17, 2000
Amendment

angiofibroma; [disease of excessive or abnormal stimulation of endothelial cells,] Crohn's disease, atherosclerosis, scleroderma, [and] hypertrophic [scars] scarring, [diseases that have angiogenesis as a pathologic consequence,] adhesions, [scarring following transplantation,] cirrhosis of the liver, pulmonary fibrosis following acute respiratory distress syndrome or other pulmonary fibrosis of the newborn, endometriosis, polyposis, obesity, uterine fibroids, prostatic hypertrophy, and amyloidosis.

10. (amended) The method of claim 1 wherein the enzyme is administered [topically or] locally at or adjacent a site in need of treatment.

Please add new claims 26 and 27:

26. The method of claim 1 wherein the individual has a disorder in which angiogenesis is involved, the disorder being selected from the group consisting of disease of excessive or abnormal stimulation of endothelial cells, diseases that have angiogenesis as a pathologic consequence, and scarring following transplantation,

27. The method of claim 1 wherein the enzyme is administered topically.

Remarks

Rejections under 35 U.S.C. 112

Claims 1-11 and 19-25 were rejected under 35 U.S.C. 112, first paragraph, as not enabled for glycosaminoglycan degrading enzymes in general. Claims 2, 6-8, 19, 21, and 25 were rejected under 35 U.S.C. 112, second paragraph, as indefinite. These rejections are respectfully traversed if applied to the amended claims.